Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.010 Biomarker group BEFREE ITM support for patients with chronic respiratory and cardiovascular diseases: a protocol for a randomised controlled trial. 30826759 2019
CUI: C0677886
Disease: Epithelial ovarian cancer
Epithelial ovarian cancer
0.010 Biomarker disease BEFREE Here, we interrogated the presence and clinical relevance of OVCA t-HET. 30446274 2019
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion
0.010 AlteredExpression phenotype BEFREE In addition, SLC22A18 knockdown decreased the expression of insulin-like growth factor-binding protein 1 (IGFBP-1) and increased the invasion ability of HepG2 cells. 30635741 2019
CUI: C4721610
Disease: Carcinoma, Ovarian Epithelial
Carcinoma, Ovarian Epithelial
0.010 Biomarker disease BEFREE Here, we interrogated the presence and clinical relevance of OVCA t-HET. 30446274 2019
Squamous cell carcinoma of esophagus
0.010 AlteredExpression disease BEFREE Expression of lncRNA GAS5 was downregulated in the ESCC tissues compared with adjacent normal tissues, and was also downregulated in ESCC Kyse450 cells compared with the human esophageal epithelial HET-1A cell line. 30008868 2018
CUI: C0555198
Disease: Malignant Glioma
Malignant Glioma
0.010 AlteredExpression disease BEFREE Immunohistochemical analysis of malignant glioma specimens demonstrated a significant positive correlation between the levels of MGMT and SATB1, and a negative correlation between the levels of SLC22A18 and SATB1. 30140041 2018
CUI: C0584960
Disease: Factor V Leiden mutation
Factor V Leiden mutation
0.010 GeneticVariation disease BEFREE - During a 2.5-year period, we compared 4 groups of patients (n = 60): FVL heterozygous (FVL-HET)/taking rivaroxaban, wild-type/taking rivaroxaban, FVL-HET/no rivaroxaban, and normal APCR/no rivaroxaban. 28920711 2018
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis
0.010 Biomarker disease BEFREE Atherosclerosis was diagnosed by (carotid and femoral) ITM measurement and ABPI. 28146208 2017
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.010 Biomarker disease BEFREE Atherosclerosis was diagnosed by (carotid and femoral) ITM measurement and ABPI. 28146208 2017
CUI: C0007134
Disease: Renal Cell Carcinoma
Renal Cell Carcinoma
0.010 GeneticVariation disease BEFREE We identified ARHGDIG , ATP1A1 , SCNN1B and SLC8A3 as ITM genes exhibiting RCC-specific promoter methylation and down-regulation. 27789672 2017
CUI: C0030193
Disease: Pain
Pain
0.010 Biomarker phenotype BEFREE Eighty patients were randomized to receive either intrathecal morphine (Group ITM) or local infiltration analgesia (Group LIA) for pain management in a double-blind study. 28856511 2017
CUI: C0030201
Disease: Pain, Postoperative
Pain, Postoperative
0.010 Biomarker phenotype BEFREE The findings suggest that a single dose of ITM before hepatic/pancreatic surgery may offer better postoperative pain control than i.v. opioid administration during surgery. 27885425 2017
CUI: C0563625
Disease: Agnosia for Pain
Agnosia for Pain
0.010 Biomarker disease BEFREE Eighty patients were randomized to receive either intrathecal morphine (Group ITM) or local infiltration analgesia (Group LIA) for pain management in a double-blind study. 28856511 2017
CUI: C3539878
Disease: Triple Negative Breast Neoplasms
Triple Negative Breast Neoplasms
0.010 Biomarker disease BEFREE Application of CLImAT-HET to 5 primary triple negative breast cancer samples demonstrates its ability to capture clonal diversity in the CAN/LOH dimensions. 28298214 2017
CUI: C4722518
Disease: Triple-Negative Breast Carcinoma
Triple-Negative Breast Carcinoma
0.010 Biomarker disease BEFREE Application of CLImAT-HET to 5 primary triple negative breast cancer samples demonstrates its ability to capture clonal diversity in the CAN/LOH dimensions. 28298214 2017
CUI: C0030421
Disease: Paraganglioma
Paraganglioma
0.010 Biomarker disease BEFREE Of the 60 SDHD tumours investigated, four tumours showing retention of chromosome 11 showed SLC22A18 and CDKN1C expression levels comparable to levels in tumours showing loss of chromosome 11, suggesting loss of protein expression despite chromosomal retention.Our data strongly suggest that SLC22A18 and/or CDKN1C are tumour modifier genes involved in the tumourigenesis of SDHD-linked paraganglioma. 27402879 2016
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
0.010 Biomarker disease BEFREE In conclusion, these findings offer the convincing evidence that the roles of SLC22A18 in NSCLC progression may be partially caused by the regulatory effects of miR-137, which may function as a tumor suppressor. 25498886 2015
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.010 AlteredExpression disease BEFREE We first showed that the expression of SLC22A18 is significantly down-regulated in tumor tissues using matched normal-tumor samples from CRC patients. 26196590 2015
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.010 GeneticVariation group BEFREE SLC22A18, solute carrier family 22, member 18, has been proposed to function as a tumor suppressor based on its chromosomal location at 11p15.5, mutations and aberrant splicing in several types of cancer and down-regulation in glioblastoma. 26196590 2015
Malignant neoplasm of colon and/or rectum
0.010 Biomarker disease BEFREE Characterization of SLC22A18 as a tumor suppressor and novel biomarker in colorectal cancer. 26196590 2015
CUI: C0175694
Disease: Smith-Lemli-Opitz Syndrome
Smith-Lemli-Opitz Syndrome
0.010 GeneticVariation disease BEFREE Another innovative aspect of this study is that it provides a reliable and highly reproducible measurement of 7-DHC in 7-dehydrocholesterol reductase (Dhcr7)-HET mouse (a model for Smith-Lemli-Opitz syndrome) samples, showing regional differences in the brain tissue. 24259532 2014
CUI: C0017168
Disease: Gastroesophageal reflux disease
Gastroesophageal reflux disease
0.010 Biomarker disease BEFREE The data support the validity of HET-1A cells as a model of the response of the human esophageal mucosa in GERD. 22790593 2012
CUI: C0027051
Disease: Myocardial Infarction
Myocardial Infarction
0.010 Biomarker disease BEFREE The HET mice showed exacerbated left ventricular (LV) contractile dysfunction, dilatation, and remodelling compared with WT mice 28 days after MI. 22202974 2012
Familial multiple trichoepitheliomata
0.010 AlteredExpression disease BEFREE Normal esophageal epithelium and HET-1A cells (derived from normal squamous epithelium) show high levels of Beclin-1, but lower levels of Beclin-1 were found in BE and EAC cell lines (CP-A, CP-C, and OE33). 22301112 2012
CUI: C0004364
Disease: Autoimmune Diseases
Autoimmune Diseases
0.010 GeneticVariation group BEFREE Polymorphisms of the NACHT [neuronal apoptosis inhibitory protein (NAIP), CIITA, HET-E, TP1] and leucine-rich repeat protein 1 (NLRP1) gene are reported to be associated with susceptibility to vitiligo and several autoimmune diseases. 21331694 2011